Top news of the week: 21.04.2020.
#COVID19 #ForbesMidas #Biotech #coronavirus #VentureCapitalists #StockMarket #VCs #startups #NASDAQ #biopharma
Startups
#Biotech #VentureCapitalists are continuing efforts to launch new drug #startups despite #COVID19 disruptions. In fact, #VCs may be able to consider more new #biotech opportunities now that videoconferences have replaced travel to meetings https://t.co/QmPQHWwlFx @WSJ
OpenBiotech VCs Steer Around Covid-19 Obstacles
Investors at firms such as Atlas Venture, Third Rock Ventures, Avalon Ventures, ARCH Venture Partners and MPM Capital say they are finding ways to continue launching and building biotech ...
Here's how one top biotech investor eyes healthcare in a post-coronavirus world: https://t.co/9v5LbVJjWV #ForbesMidas https://t.co/VhJkskfpZ7
Open‘We’ll See Some Pretty Big Changes’: How One Top Biotech Investor Eyes Healthcare In A Post-Coronavirus World
Arch Venture Partners' managing director, Kristina Burow, sees the healthcare sector poised to come out stronger as it innovates against COVID-19.
.@Sanofi and @GSK collaborate to speed up #coronavirus #vaccine development https://t.co/hlIt7dxyTQ
OpenSanofi and GlaxoSmithKline collaborate to speed up coronavirus vaccine development
Sanofi plans to use technology from GlaxoSmithKline to accelerate the development of its experimental vaccine against the novel coronavirus.
"Combining sustained public market appetite, good performances by crossover investors and traditional funds working with new or recently raised assets, we believe that the healthy run in biopharma will continue."
#biopharma #StockMarket #NASDAQ #IPOs
https://t.co/2NZZlB8dXg
Open‘The silver lining:’ Biotech IPOs in the time of coronavirus
The COVID-19 pandemic has upended the public markets, leading to a “disastrous” first quarter and “throwing a wrench” in what Renaissance Capital once expected to be the most productive IPO ...
Welcome to GV. @Cerevance takes a differentiated approach to neurotherapeutics, creating new medicines for patients with serious diseases / @brobbs @schenkein – https://t.co/dN3FrM5Bkm
OpenGates, GV chip into $45M round for CNS biotech Cerevance
Four months after inking its first Big Pharma partnership, Cerevance is topping up its coffers with a $45 million raise. The proceeds will push the company’s lead Parkinson’s disease ...
RT @LifeSciVC: Value Creation And Destruction: Dispersion of Performance In Biotech IPOs. https://t.co/ScOuFAD0hl
$75B in net value creation in the current 2013-2020 super-cycle. Majority driven by very few big winners. And M&A deals. https://t.co/0rrH1jlgKH
OpenValue Creation And Destruction: Dispersion of Performance In Biotech IPOs
The biotech IPO market in 2020 remains strong, despite the volatility and COVID headwinds. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this ...
The NIH's partnership with 16 drugmakers has been named "Accelerating COVID-19 Therapeutic Interventions and Vaccines."
#COVID19
https://t.co/8JCRbEVsWJ
OpenNIH spearheads broad partnership with drugmakers, regulators to speed COVID-19 therapies
The initiative reflects the urgency for drugmakers to work together, rather than independently, to advance promising treatments for the novel coronavirus.
How Covid-19 Is Impacting First Fundings To Startups In 3 Major US Tech Hubs https://t.co/wlWdP8Frq6
OpenHow Covid-19 Is Impacting First Fundings To Startups In 3 Major US Tech Hubs
Recently, we’ve analyzed how the Covid-19 pandemic has affected overall startup funding, seed-stage investments, and corporate venture capital investments. In this post, we take a look at ...